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Abstract
Ornithine decarboxylase (ODC) is the rate-limiting enzyme in the biosynthesis of polyamines, a family of cationic
compounds required for optimal cell proliferation and differentiation. Within mammalian melanocytes, the expression of
genes regulating cell growth and/or differentiation can be controlled by K-melanocyte-stimulating hormone (KMSH) and
other melanogenesis modulating agents. In the B16 mouse melanoma model, KMSH stimulates melanogenesis by
upmodulation of tyrosinase (tyr) activity, whereas the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) inhibits
melanin synthesis. Therefore, we analyzed the regulation of ODC by these agents, as related to changes in the melanogenic
pathway. Treatment of B16 cells with TPA or KMSH rapidly stimulated ODC activity. The effect was stronger for TPA and
appeared mainly posttranslational. Irreversible inhibition of ODC with the active site-directed inhibitor K-difluoromethyl-
ornithine (DFMO) did not block TPA-mediated inhibition of tyr. Conversely, prolonged treatment of B16 cells with DFMO
stimulated tyr activity by a posttranslational mechanism, probably requiring polyamine depletion. Combination treatment
with KMSH and DFMO synergistically activated tyr. Therefore, ODC induction is not involved in the melanogenic response
of B16 cells to KMSH. Rather, increased intracellular concentrations of polyamines following ODC induction might
constitute a feedback mechanism to limit melanogenesis activation by KMSH. ß 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Mammalian melanogenesis is a complex pathway
restricted to specialized cells, the melanocytes, and
leading to the formation of colored melanin poly-
mers from the amino acid L-tyrosine. Melanin syn-
thesis is catalyzed by at least three enzymatic pro-
teins, tyrosinase (tyr, monophenol dihydroxyphenyl-
alanine:oxygen oxidoreductase, EC 1.14.18.1) and
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the tyr-related proteins (tyrps) 1 and 2. Tyr catalyzes
the rate-limiting generation of L-dopaquinone from
L-tyrosine and is also able to oxidize L-3,4-dihydrox-
yphenylalanine (L-DOPA) to L-dopaquinone [1].
L-Dopaquinone evolves spontaneously into a semi-
stable intermediate, L-dopachrome, which is con-
verted into 5,6-dihydroxyindole-2-carboxylic acid
(DHICA) by dopachrome tautomerase (Dct, tyrp2)
[2]. Finally, mouse tyrp1 [3,4] and human tyr [5] are
able to oxidize DHICA to the corresponding 5,6-in-
dolequinone-2-carboxylic acid, thus promoting its in-
corporation into eumelanin.
In mammalian melanocytes, the enzymatic activity
of the rate-limiting tyr is regulated by a variety of
extracellular signals. Physiologic melanogenic stimuli
include UV radiation and K-melanocyte-stimulating
hormone (KMSH) or other peptide hormones, collec-
tively termed melanocortins [6]. KMSH stimulates
the di¡erentiation and/or proliferation of mammali-
an melanocytes [7], by binding to the melanocortin 1
receptor (MC1R) and triggering the cAMP signaling
pathway [8]. The molecular mechanisms of the stim-
ulation of melanogenesis by KMSH have been inten-
sively investigated using mouse melanoma cells as a
model [9^11]. In these cells, activation of the cAMP
pathway causes a strong transcriptional induction of
the tyr gene, mainly through a robust induction of
the microphthalmia (Mitf) transcription factor [12^
14]. Conversely, the hormonal e¡ects on tyrp1 and
Dct gene expression and on the corresponding enzy-
matic activities are modest [11,15]. Other signaling
pathways are also involved in the control of melano-
genesis. For instance, protein kinase C (PKC) has
been reported to strongly activate melanogenesis in
human melanocytes [16] but to decrease Mitf expres-
sion and tyr activity in B16 mouse melanoma cells
[17]. Similarly, activation of the MAPK pathway ap-
pears to trigger an inhibition of melanogenesis within
B16 cells [18]. Therefore, multiple signaling pathways
contribute to the control of melanogenesis, whose
complexity could be increased by a possible cross-
talk between them.
The polyamines putrescine, spermine and spermi-
dine are ubiquitous low molecular weight cationic
compounds required for optimal cell proliferation
and/or di¡erentiation [19]. Ornithine decarboxylase
(ODC) is the key, rate-limiting enzyme in polyamine
biosynthesis, and catalyzes the decarboxylation of
L-ornithine to yield putrescine. In keeping with its
important role in the regulation of cellular prolifer-
ation and di¡erentiation, ODC gene expression and
enzyme activity are tightly controlled by a variety of
extracellular signaling molecules in eukaryotic cells
[20]. Regulatory mechanisms include the modulation
of ODC mRNA levels by transcriptional and post-
transcriptional e¡ects, the regulation of its rate of
translation [21,22], covalent posttranslational modi¢-
cation of the enzyme, and changes in the extremely
short half-life of the protein [23] or in the levels of
e¡ector proteins able to modulate ODC activity
through speci¢c interactions [24,25].
Several observations suggest that ODC and poly-
amines might be involved in various aspects of
skin biology, including the regulation of melanogen-
esis. UV radiation induces ODC activity in the skin
[26]. Inhibition of ODC with the irreversible inhibi-
tor K-di£uoromethylornithine (DFMO) enhances the
melanogenic activity of mouse melanoma cells [27],
and spermine, at concentrations in the low milli-
molar range, inhibits mouse melanoma tyr [28]. In
the light of these observations, it is surprising
that little attention has been paid to the regulation
of ODC activity in mammalian melanocytes and
melanoma cells, as related to the control of pigmen-
tation.
Here we report a study on the regulation of ODC,
at the gene expression, protein and enzyme activity
levels, in the well established B16 mouse melanoma
model. We have also analyzed its possible involve-
ment in the control of the rate of the melanogenic
pathway. Our results show that ODC mRNA and
protein levels, as well as ODC enzymatic activity
are upregulated by 12-O-tetradecanoylphorbol 13-
acetate (TPA), although to di¡erent extents. Con-
versely, KMSH moderately and transiently downre-
gulates ODC mRNA, but has no detectable e¡ect on
ODC protein levels, and triggers a modest activation
of its enzymatic activity. Therefore, within B16 mel-
anoma cells the regulation of ODC is complex and
apparently involves transcriptional, translational and
posttranslational e¡ects. Moreover, polyamine deple-
tion increases tyr activity by a posttranslational
mechanism that synergistically potentiates the stim-
ulatory action of KMSH.
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2. Materials and methods
2.1. Reagents
The radioactive substrates L-[3,5-3H]tyrosine and
L-[1-14C]ornithine were from Amersham Pharmacia
Biotech (Little Chalfont, Buckinghamshire, UK)
and Moravek Biochemicals (Brea, CA, USA), respec-
tively. L-Tyrosine, dithiothreitol, pyridoxal phos-
phate, Igepal CA-630, BSA, L-DOPA, phenylmethyl-
sulfonyl £uoride (PMSF), the superpotent KMSH
analogue [Nle4, D-Phe7] KMSH (from now on termed
KMSH), synthetic melanin and bicinchoninic acid
were from Sigma (St. Louis, MO, USA), DFMO
was obtained from Ilex Oncology (San Antonio,
TX, USA). Reagents and plasticware for cell culture
were from Nunc (Roskilde, Denmark) or Gibco
(Gaithersburg, MD, USA). Other reagents were
from Merck (Darmstadt, Germany) or Prolabo (Bar-
celona, Spain).
2.2. Cell culture and treatments
B16 mouse melanoma cells were cultured in MEM
supplemented with 10% FCS, 2 mM glutamine, 100
U/ml penicillin and 100 WU/ml streptomycin. KMSH,
TPA and DFMO were used at 1037 M, 25 ng/ml and
0.1 mM respectively. Cultures were serum-deprived
24 h before addition of the agents. Cells were har-
vested with trypsin, washed with PBS, and solubi-
lized in 10 mM sodium phosphate, pH 6.8, 1% Igepal
CA-630, 0.1 mM EDTA, and 0.1 mM PMSF. The
extracts were centrifuged (20 000Ug, 30 min) before
enzyme activity assays.
2.3. Enzyme activity determinations
Tyrosine hydroxylase activity was determined by a
radiometric method [29] and DOPA oxidase activity
was measured spectrophotometrically, in the pres-
ence of 3-methyl-2-benzothiazolinone hydrazone
[30]. ODC activity was monitored by a radiometric
procedure based on the determination of 14CO2 re-
lease from L-[1-14C]ornithine, as described elsewhere
[31].
2.4. Western blot
Western blotting was performed as described [5],
using the speci¢c anti-tyr polyclonal antiserum
KPEP7 (a gift from Prof. V. Hearing, NIH, Bethes-
da, MD, USA) or a commercial monoclonal anti-
ODC antibody (Sigma) as primary antibodies. Cells
were solubilized as for enzyme activity measure-
ments, and equal amounts of protein were loaded
in each lane of 12% SDS^PAGE gels. Transfer was
carried out in a semi-dry unit from Bio-Rad (Her-
cules, CA, USA) and checked by Coomassie blue
staining of the gel. Before blocking, the lower por-
tion of the membrane was cut and stained for total
protein with Amido black to ascertain comparable
loading and transfer. Staining of immunoreactive
bands was done with a chemiluminescent substrate
from Amersham Pharmacia. Quanti¢cation of the
blots was performed in a Gel Doc system (Bio-
Rad) using the Multi-Analyst software.
2.5. Northern blot
Total RNA was isolated with guanidinium thio-
cyanate, denatured with glyoxal and DMSO, electro-
phoresed on 1.5% agarose gels in 10 mM sodium
phosphate bu¡er, pH 7.0, and transferred to Hybond
nylon membrane. Prehybridization and hybridization
were performed as described [32]. The random prim-
ing 32P-labeled probes used were: tyr : 1.6 kb EcoRI
fragment from plasmid pMEL34 [33]; ODC : 550 bp
PCR fragment (primers GGATTTGACTGTGCA-
AGC and GAGTCTGATGGGAAGTAC); Mitf :
1.3 kb PCR fragment (primers AAGTGGTCTGC-
GGTGTCTCC and AAGGCAGGCTCGCTAAC-
ACG).
PCR fragments were generated using cDNA from
B16 melanocytes as target. Their identity was ascer-
tained by restriction mapping. Signal intensities were
quanti¢ed by phosphorimaging and normalized to
the GAPDH signal.
2.6. Other procedures
Protein was determined by the bicinchoninic acid
method using BSA as standard. Data were statisti-
cally analyzed by Student’s t-test, using the Graph-
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Pad Prism software, and a signi¢cant level of di¡er-
ence was set at P6 0.05.
3. Results
3.1. Regulation of ODC gene expression in B16
melanocytes
Since ODC behaves as an early gene in many cel-
lular systems, we analyzed ODC mRNA levels in B16
cells treated with KMSH or TPA for short times,
ranging from 1 to 16 h. The response of ODC
mRNA levels to KMSH was biphasic (Fig. 1A). A
rapid and transient decrease, with maximal inhibition
of about 30%, was followed by an increase in ODC
mRNA, up to 170% of control levels 8 h after addi-
tion of KMSH. The e¡ect was most likely cAMP-
dependent, since it could be mimicked by forskolin
(not shown). On the other hand, treatment with TPA
signi¢cantly upregulated ODC mRNA (Fig. 1B). The
maximal stimulation achieved by TPA was approx.
2-fold, after 8 h of treatment. However, in this case,
ODC mRNA induction was not preceded by an ini-
tial and transient downregulation, as observed for
KMSH.
3.2. Regulation of ODC activity and protein levels
The activating e¡ect of TPA on ODC enzymatic
activity was much stronger than the induction of
ODC gene expression (Fig. 2A). It was also faster,
since the maximal induction was reached 4 h (instead
of 8 h) after addition of the phorbol ester to the
culture medium. The stimulation of ODC enzymatic
activity was also much higher than the increase in
protein abundance, as detected by Western blot
(Fig. 2B). In cells treated with KMSH, and in spite
Fig. 2. TPA induction of ODC enzymatic activity and protein
in B16 cells. (A) Strong induction of ODC activity by TPA.
Cells treated as in Fig. 1 were trypsinized and solubilized for
enzyme activity measurements at the times shown. Results
(mean þ S.D., n = 4) are expressed as % speci¢c ODC activity
relative to controls harvested at the same time as the experi-
mental points. (B) Western blot analysis of ODC protein
changes in TPA-treated cells. Cells were harvested at the times
shown, and ODC was detected by Western blot using a speci¢c
monoclonal antibody. Similar trends were obtained in two dif-
ferent experiments. Note that the increase in protein abundance
is much lower than the stimulation of ODC enzymatic activity.
Fig. 1. Regulation of ODC mRNA levels by KMSH and TPA.
Semicon£uent B16 mouse melanoma cells were serum-deprived
24 h before addition of KMSH (1037 M, ¢nal concentration,
A) or TPA (25 ng/ml, B). Cells were lysed with guanidinium
thiocyanate at the times shown, and total RNA was extracted
and analyzed by Northern blot. For each panel, a representa-
tive blot is shown on the left and the kinetics of the relative
ODC mRNA changes, corrected for loading with a GAPDH
probe and quanti¢ed by phosphorimaging, on the right (shown
as mean þ S.D., nv3). C stands for control, untreated cells. In
the experiment described in A, two independent controls were
collected along with the 1 h and 16 h time points, to correct
for possible changes in the basal expression of the ODC gene.
Since no signi¢cant variations were found, the 16 h control was
omitted in the experiment shown in B.
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of the transient downregulation of ODC mRNA lev-
els, ODC enzymatic activity increased rapidly and
moderately, up to 2-fold (Fig. 3A). This increase
was, however, small as compared to the potent in-
duction achieved by TPA. Consistent with a limited
e¡ect on enzymatic activity, changes in ODC protein
levels were minor, as detected by Western blot of
extracts from cells treated with the hormone (Fig.
3B).
3.3. Inhibition of ODC with DFMO does not block
tyr downregulation by TPA, and synergistically
potentiates tyr activation by KMSH
Since both TPA and KMSH signi¢cantly activated
ODC activity in B16 cells, we next examined whether
a blockade of this activation would interfere with
either the inhibition of tyr activity mediated by
TPA or its activation in response to KMSH. This
study was performed by treating B16 melanoma cells
with TPA or KMSH in the presence of DFMO, a
strong, speci¢c and irreversible inhibitor of ODC.
As previously reported by others [27], treatment of
B16 melanocytes with DFMO caused a slow activa-
tion of both the tyrosine hydroxylase and DOPA
oxidase activities of tyr (Fig. 4A). Activation was
statistically signi¢cant only after a 48 h treatment,
and similar in extent and kinetics for the two enzy-
matic activities. Tyr activation by DFMO occurred
with a smaller increase in tyr mRNA (1.5-fold), but
without changes in enzyme abundance, as detected
by Western blot with the speci¢c antibody KPEP7
(Fig. 4B,C). Therefore, tyr activation by DFMO
treatment is most likely carried out at the posttrans-
lational level.
Fig. 4. Activation of tyr in B16 melanoma cells treated with
DFMO. (A) Time course of induction of the tyrosine hydroxy-
lase (closed bars) and the DOPA oxidase (open bars) activities
of tyr. Results are the mean þ S.D. for triplicate experiments.
Basal levels of tyrosine hydroxylase and DOPA oxidase activ-
ities were 138 þ 22 WU/mg protein and 9.5 þ 2.4 mU/mg protein,
respectively. (B) Northern blot analysis of tyr mRNA changes
after DFMO treatment (72 h). A small increase in tyr mRNA
abundance was noticed in two independent experiments.
(C) Lack of upregulation of tyr protein in cells treated with
DFMO. B16 cells were grown in the presence of DFMO for
72 h and analyzed by Western blot using the speci¢c antiserum
KPEP7. Similar trends were obtained in two experiments.
Fig. 3. KMSH activation of ODC without a parallel change in
protein abundance. (A) Time course of ODC activity changes.
Cells were treated with 1037 M KMSH for the times shown.
Results (mean þ S.D., n = 4) are expressed as % ODC with re-
spect to control cultures. (B) Lack of signi¢cant modulation of
ODC protein. Cells were solubilized and their ODC contents
were analyzed by Western blot. Similar trends were obtained in
two di¡erent experiments.
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In cells treated simultaneously with DFMO and
TPA, tyr activity levels were smaller than in control
cells, even after a 72 h treatment (Fig. 5A). Inhibi-
tion of tyr activity by TPA was quantitatively similar
in the presence or absence of DFMO (when com-
pared to DFMO-treated cells or untreated controls,
respectively). Conversely, inhibition of ODC with
DFMO potentiated synergistically the stimulatory
action of KMSH on tyr. After a 48 h treatment,
the combination treatment caused activations higher
than 400%, whereas KMSH only achieved a 2-fold
activation and the e¡ect of DFMO was still not evi-
dent (Fig. 5B). Longer treatments could not be
achieved since they proved to be toxic to B16 cells.
Extensive cell death was observed at 72 h in the
presence of both KMSH and DFMO, but not of
either agent acting independently. This might be
the result of the potent synergistic induction of tyr,
since melanogenic intermediates are highly cytotoxic
species [34], owing to their ability to react with pro-
teins [35] and nucleic acids [36].
Northern blot analysis of tyr mRNA abundance
revealed that the increases mediated by DFMO and
Fig. 6. Lack of synergistic upregulation of tyr mRNA by com-
bined treatment with KMSH and DFMO. (A) Northern blot
analysis of tyr mRNA abundance in B16 cells treated with
DFMO and/or KMSH. Cells were treated as indicated, for 48 h,
before analysis of tyr mRNA abundance by Northern blot. The
experiment was repeated twice with similar results. Quanti¢ca-
tion of the blots is shown on the right (shown as relative levels
of tyr mRNA, mean þ range for two independent experiments,
and normalized to the GAPDH mRNA signal). (B) Mitf
mRNA is not upregulated by DFMO. B16 melanoma cells
were treated (2 h) with DFMO and/or KMSH. Total RNA was
extracted and analyzed for Mitf mRNA levels by Northern
blot. A representative blot is shown (left), and the histogram
on the right shows the results of the quantitative analysis of the
signals, presented as in A.
Fig. 5. Failure of DFMO to prevent TPA-mediated tyr activity
downregulation, and synergistic stimulation of tyr in the pres-
ence of KMSH. (A) Kinetics of tyrosine hydroxylase activity
changes in B16 cells treated with DFMO (open bars), TPA
(hatched bars) or both agents simultaneously (closed bars). Re-
sults are the mean þ S.D. for triplicate experiments, and are ex-
pressed as % activity with respect to controls harvested simulta-
neously. (B) Synergistic activation of tyr by DFMO and
KMSH. Cells were treated for the times shown with DFMO
alone (open bar), KMSH (hatched bars), or both agents (closed
bars). Results are expressed as in A.
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KMSH were additive, rather than synergistic. More-
over, DFMO by itself had little, if any, e¡ect on Mitf
gene expression, and failed to increase the induction
of Mitf gene expression by KMSH (Fig. 6).
4. Discussion
ODC is the rate-limiting enzyme in the biosynthe-
sis of polyamines, a group of small aliphatic cationic
molecules known to play a key role in the regulation
of cell proliferation and di¡erentiation [19]. ODC is
rapidly and transiently induced by a variety of mito-
genic signals [20]. Within the skin, overexpression of
ODC induces tumor promotion in mice [37] and
treatment of keratinocytes with the tumor promoter
TPA also increases ODC activity [38]. Therefore,
ODC and the polyamines are certainly involved in
the control of the proliferation of skin cells. More-
over, several observations also suggest a possible in-
volvement of polyamines in the regulation of the
di¡erentiation of skin cells, including melanocytes
[26^28]. However, neither the regulation of ODC ac-
tivity in melanocytes or melanoma cells, nor the pos-
sible connections between ODC activity changes and
their melanogenic status, have been studied in detail.
Using the well established B16 mouse melanoma
model, we have analyzed the regulation of ODC ac-
tivity by TPA, an agent known to decrease the mel-
anogenic activity of B16 cells [17], and by KMSH, a
potent inducer of melanogenesis. For this purpose,
the levels of ODC mRNA, protein and the enzymatic
activity were analyzed in kinetic experiments.
In many cellular systems treated with ODC-stim-
ulating agents, upregulation of ODC mRNA is
smaller than the increases in ODC protein and/or
activity [39]. In B16 melanocytes treated with TPA,
a very strong increase in ODC activity was observed.
However, only a modest upmodulation of ODC
mRNA (2-fold), and a comparable elevation of pro-
tein levels was associated to this much larger stimu-
lation of enzyme activity. Moreover, maximal activa-
tion of ODC occurred at 4 h, thus preceding
maximal induction of mRNA. In addition, 2 h after
addition of TPA to the culture medium ODC protein
levels were already higher than those of the controls,
whereas ODC mRNA was not signi¢cantly di¡erent
in control and TPA-treated cells. Thus, as in other
cell types, TPA regulates ODC activity in B16 mela-
noma cells mainly by posttranscriptional and/or
posttranslational mechanisms, probably involving
PKC activation.
When compared to the potent induction of ODC
activity by TPA, the e¡ects of KMSH were relatively
minor. In B16 cells treated with the melanocortin, a
moderate elevation of ODC enzymatic activity pro-
ceeded without noticeable changes in protein levels.
Moreover, at short treatment times where ODC ac-
tivation was maximal, ODC mRNA levels appeared
slightly decreased. The e¡ects of KMSH are most
likely mediated by cAMP, since (i) forskolin was
able to mimic the changes in ODC mRNA levels
(results not shown), and (ii) in other cell types and
tissues inhibition of protein kinase A abolishes the
induction of ODC elicited by peptidic hormones [31].
Concerning the mechanism of activation, comparison
of the changes in ODC mRNA, protein and enzy-
matic activity clearly shows that induction of ODC
activity is again most likely exerted at a posttransla-
tional level. However, our data do not allow to iden-
tify which one of the possible posttranslational
events known to be involved in the regulation of
ODC activity is the actual target of the hormone.
An interesting possibility is a downregulation of the
antizyme, a protein essential for ODC regulation
[25]. In keeping with this possibility, the antizyme
is expressed by human melanoma cells, and its intra-
cellular concentration is regulated by extracellular
signaling molecules [40]. Moreover, the possibility
exists that phosphorylation of ODC may increase
the catalytic e⁄ciency of the enzyme [41].
We also analyzed the possible involvement of
ODC activity in the regulation of melanogenesis in
B16 cells. Sustained inhibition of ODC with the irre-
versible and speci¢c inhibitor DFMO caused a slow
activation of tyr. This activation occurred with a
small increase in tyr mRNA, but without changes
in protein abundance. The modest increase in tyr
mRNA might not be related to a stimulation of tyr
gene transcription, since DFMO had little, if any,
e¡ect on the expression of Mitf, the key transcrip-
tional activator of tyr gene expression. Alternatively,
polyamine depletion following prolonged ODC inhi-
bition might lead to a stabilization of tyr mRNA,
thus increasing its levels. The ability of polyamines
to interact with nucleic acids is well documented and
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polyamine depletion has been shown to increase the
half-life of certain mRNA species, leading to parallel
changes in their abundance [42,43]. A possible e¡ect
of polyamines in the stability of mRNAs for several
melanocyte di¡erentiation markers will be analyzed
in the near future. In any case, the ¢nding that tyr
activity is stimulated by polyamine depletion without
changes in tyr protein contents indicates that, again
in this case, the mechanism of activation is clearly
posttranslational, and probably involves the reversal
of tyr inhibition by polyamines [28]. Accordingly, the
e¡ect of DFMO is slow, and a 48^72 h treatment of
melanocytes is needed to observe a clear-cut activa-
tion of tyr. This time is likely required to deplete the
intracellular polyamine pool of B16 cells, under con-
ditions of inhibited synthesis of new polyamines [27].
Consistent with a posttranslational activation of
tyr, treatment of B16 cells with DFMO synergistical-
ly enhanced tyr stimulation by KMSH. In mouse
melanoma cells, the hormone is known to increase
the intracellular levels of the protein [10,11]. There-
fore, combined treatment of melanocytes with
KMSH and DFMO would result in higher levels of
enzyme, with higher speci¢c activity, thus accounting
for the synergistic activation observed in our study.
It is worth noting that the combination treatment
was extremely cytotoxic at incubation times longer
than 48 h with extensive cell death being observed
at 72 h. A similar observation has already been re-
ported by others, using DFMO chemically coupled
to KMSH fragments [44]. Conceivably, a limited cell
death may also occur at 48 h, a¡ecting preferentially
high tyr activity cells. Should this be the case, the
measured synergistic e¡ect may re£ect the behavior
of the lower tyr activity cell population. Therefore,
the actual synergistic potentiation of KMSH melano-
genic action by DFMO might be even higher than
the one reported above.
In summary, prolonged inhibition of ODC activity
in B16 mouse melanoma cells causes a posttransla-
tional activation of tyr. It can be hypothesized that
the treatments leading to ODC activation could de-
crease tyr activity, whereas inhibition of ODC lead-
ing to a decreased intracellular polyamine pool
would exert a melanogenic e¡ect. Moreover, since
this melanogenic e¡ect is posttranslational in nature,
ODC inhibition might act synergistically with treat-
ments increasing the intracellular levels of the tyr
protein. The physiological relevance of these ¢nd-
ings, as related to the control of mammalian pigmen-
tation, is, at present, di⁄cult to evaluate. If the
KMSH-triggered activation of ODC results in an in-
creased intracellular polyamine concentration, this
might constitute a negative feedback mechanism to
moderate the melanogenic action of the hormone.
This e¡ect could be ampli¢ed if polyamines tend to
concentrate in certain subcellular compartments,
such as the melanosomes, by virtue of their positive
charge. A higher concentration of polyamines in the
melanosome is likely, since a variety of positively
charged molecules have been shown to accumulate
in melanized tissues by binding to the negatively
charged melanin polymer [45]. Moreover, negative
feedback mechanisms acting on the melanogenic
pathway appear quite common. For instance, UV
light increases the production of TNFK in the skin
[46], and this cytokine acts as a potent inhibitor of
tyrosinase in both human [47] and mouse [48] mela-
nocytes and melanoma cells. Moreover, H2O2, a
product of the melanogenic pathway, also inhibits
tyr activity and gene expression [49]. These negative
regulatory mechanisms are usually interpreted as
melanocyte-speci¢c defensive processes, that would
limit the cytotoxicity inherent to an excessive rate
of melanogenesis [47]. However, a ¢nal assessment
of the role of ODC in the modulation of the mela-
nogenic e¡ect of KMSH will only be possible after
the measurement of polyamines levels in di¡erent
subcellular compartments of control and hormone-
treated cells.
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